Lancet: Study on Alzheimer's biomarker characteristics in patients with Down syndrome

Alzheimer's disease and its complications are the leading cause of death in adults with Down syndrome, and researchers recently examined how Alzheimer's biomarkers change in adult populations with Down syndromestudies were conducted in Spain and the United Kingdom and classified the cognitive status of the patients involved in the study according to CAMCOG-DS, who were with mild and moderate disabilities and could receive Alzheimer's biomarker assays, with the main endpoint being the sequence and age of changes in biomarkers388 people with Down syndrome participated in the study, of which 257 (66%) were asymptomatic, 48 (12%) had pre-ire Alzheimer's disease, 83 (21%) had Alzheimer's disease, and 242 control groups were recruitedThe study found that from the age of 30, People with Down syndrome began to change in CSF A beta 1-42/1-40 and plasma NFL levels; The average age at which Alzheimer's disease is diagnosed is 50.2 years, and Alzheimer's disease is 53.7 yearsThe prevalence of symptomatic Alzheimer's disease increases with age, with almost 90-100% of the disease at age 70Alzheimer's disease has a long preclinical stage in patients with Down syndrome, during which biomarkers follow a predictable sequence of changes for up to 20 years